AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial

Lilly brings heavy oncology firepower to ASCO with plenary data across cancers

The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States